Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial

被引：0
|
作者：
Von Pawel, J. [1 ]
Larson, T. [2 ]
Ou, S. I. [3 ]
Limentani, S. A. [4 ]
Sandler, A. B. [5 ]
Vokes, E. E. [6 ]
Kim, S.
Liau, K. F.
Bycott, P. W. [7 ]
Schiller, J. H. [8 ]
机构：
[1] Asklepios Fachklin Lungenkrankheiten, Abt Onkol, Gauting, Germany
[2] Hubert H Humphrey Canc Ctr, Robbinsdale, MN USA
[3] Chao Family Comprehens Canc Ctr, Orange, CA USA
[4] Blumenthal Canc Ctr, Carolinas Hematol Oncol Assoc, Charlotte, NC USA
[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[6] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[7] Pfizer Inc, San Diego, CA USA
[8] Univ Texas Southwestern, Dallas, TX USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71379-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6551
引用
收藏
页码：373 / 373
页数：1
相关论文
共 50 条
  • [21] A PHASE I STUDY OF AXITINIB (AG-013736) PLUS FOLFOX CHEMOTHERAPY AND BEVACIZUMAB IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Abhyankar, V. V.
    Sharma, S.
    Trowbridge, R. C.
    Robles, R. L.
    Tarazi, J.
    Kim, S.
    Tortorici, M.
    Hee, B.
    Burgess, R. E.
    ANNALS OF ONCOLOGY, 2008, 19 : 128 - 128
  • [22] Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: An overview
    Shepherd, FA
    ANTI-CANCER DRUGS, 1995, 6 : 19 - 25
  • [23] Single-agent mitomycin for advanced non-small cell lung cancer
    Snee, M
    CLINICAL ONCOLOGY, 2001, 13 (02) : 99 - 102
  • [24] First-line single agent of gefitinib in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II study.
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Nishiwaki, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [25] Efficacy and safety of sunitinib in a multicenter phase II trial of previously treated, advanced non-small cell lung cancer (NSCLC)
    Socinski, Mark A.
    Novello, Silvia
    Sanchez, Jose M.
    Brahmer, Julie
    Govindan, Ramaswamy
    Belani, Chandra P.
    Atkins, James N.
    Gillenwater, Heidi H.
    Palleres, C.
    Chao, Richard C.
    ANNALS OF ONCOLOGY, 2006, 17 : 218 - 218
  • [26] Impact of dosing schedule and dosing sequence on anti-tumor efficacy of combination therapy with the antiangiogenic agent (AA) axitinib (AG-013736) in xenograft tumor models of human pancreatic carcinoma and non-small cell lung cancer (NSCLC)
    Hu-Lowe, Dana
    Mathias, Adam
    Hall, Chassidy
    Chen, Enhong
    Zhang, Lianglin
    Mullin, Robert
    Hollister, Beth
    Christensen, Jamie
    CANCER RESEARCH, 2009, 69
  • [27] A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component
    Spano, J.
    Chodkiewicz, C.
    Maurel, J.
    Wong, R. P.
    Wasan, H. S.
    Pithavala, Y. K.
    Bycott, P. W.
    Liau, K.
    Kim, S.
    Rixe, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [28] Single-agent navelbine oral (NVBo) as chemotherapy (CT) in elderly patients (pts) with advanced stage or metastatic non-small cell lung cancer (NSCLC)
    Parente, B
    Queiroga, H
    Espanhol, V
    Cunha, J
    Fernandes, A
    Barroso, A
    Conde, S
    LUNG CANCER, 2005, 49 : S263 - S263
  • [29] ASSOCIATION BETWEEN DIASTOLIC BLOOD PRESSURE (DBP) ≥ 90 MMHG AND EFFICACY IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) RECEIVING AXITINIB (AG-013736; AG)
    Rixe, O.
    Dutcher, J. P.
    Motzer, R. J.
    Wilding, G.
    Stadler, W. M.
    Kim, S.
    Tarazi, J.
    Rosbrook, B.
    Rini, B.
    ANNALS OF ONCOLOGY, 2008, 19 : 189 - 189
  • [30] Phase ii trial with Docetaxel in patients (PTS) with non small cell lung cancer (NSCLC)
    Latreille, J
    Laberge, F
    Viallet, J
    Maksymiuk, A
    Shepherd, F
    Gelman, K
    Delorme, F
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1070 - 1070
12345